BeiGene’s Tevimbra Approved in China for NSCLC Patients as Neoadjuvant and Adjuvant Therapy
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has announced...
Cancer
Novartis’s Kisqali Receives Positive CHMP Opinion for Early Breast Cancer Treatment in the EU
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced that the Committee for Medicinal Products...
Astellas Pharma’s Vyloy Receives FDA Approval for Gastric Cancer Treatment in CLDN18.2 Positive Tumors
Astellas Pharma Inc. (TYO: 4503), a Japanese pharmaceutical company, has announced that it has received...
Jiangsu Hengrui Pharmaceuticals Initiates Phase III Clinical Trial for SHR-A1904 in Gastric Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Jacobio Pharma’s G12C Inhibitor Gecirasib Earns Orphan Drug Designation in Europe for Pancreatic Cancer
Jacobio Pharma (HKG: 1167), a China-based biopharmaceutical company, has announced that it has received Orphan...
Astellas Pharma’s Vyloy Receives FDA Approval for CLDN18.2 Positive Gastric Cancer Treatment
Astellas Pharma (TYO: 4503) has announced that the U.S. Food and Drug Administration (FDA) has...
Kanghong Pharmaceutical’s NASH Drug KH629 Receives Clinical Trial Implicit Approval in China
On October 18th, the official website of the Center for Drug Evaluation (CDE) of the...
Akeso Biopharma Launches Phase Ib/II Trial for Cadonilimab and AK112 in Pancreatic Cancer
On October 17, ClinicalTrials.gov reported that Akeso Biopharma (HKG: 9926) has initiated a Phase Ib/II...
FDA Extends Review of Amgen’s Lumakras for KRAS G12C mCRC Treatment to January 2025
On October 18, FirstWord reported that the U.S. FDA has extended the review period for...
Pfizer Partners with TRIANA Biomedicines to Develop Molecular Glue Degraders for Oncology and Other Diseases
Pfizer (NSE: PFIZER), a leading US pharmaceutical company, has entered into a strategic partnership and...
Tencent Invests USD 30 Million in Early Cancer Detection Firm Insighta, Backed by Prenetics
Prenetics Global Limited (NASDAQ: PRE), a prominent health sciences company with operations in the US...
Chengdu Baiyu Pharmaceutical Strikes Licensing Deal with Novartis for Unannounced Anti-Tumor Asset
Chengdu Baiyu Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, has entered into a licensing agreement...
Novocure’s Optune Lua Wins FDA Approval for mNSCLC Treatment in Combination with Immunotherapies
Novocure (NASDAQ: NVCR), a Swiss firm renowned for its pioneering Tumor Treating Fields (TTFields) cancer...
Alphamab Oncology and CSPC Pharma’s KN026 Phase III Trial for Breast Cancer Gets NMPA Approval
Alphamab Oncology (HKG: 9966) and CSPC Pharma (HKG: 1093) have jointly announced that their Phase...
Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biotech company based in...
Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...
Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor
Boehringer Ingelheim (BI), a leading German pharmaceutical company, has announced a research collaboration and license...
Huadong Medicine Gets NMPA Green Light for BCMA-Targeted ADC HDM2027 Phase I/IIa Study
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
RemeGen’s Disitamab Vedotin Receives Priority Review for New Indication in Breast Cancer by China’s NMPA
RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced that the Center...
AstraZeneca and Daiichi Sankyo’s Enhertu Receives Fourth Indication Approval in China
AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568)’s co-developed antibody drug conjugate (ADC), Enhertu (trastuzumab...